atazanavir sulfate has been researched along with chloroquine in 3 studies
Studies (atazanavir sulfate) | Trials (atazanavir sulfate) | Recent Studies (post-2010) (atazanavir sulfate) | Studies (chloroquine) | Trials (chloroquine) | Recent Studies (post-2010) (chloroquine) |
---|---|---|---|---|---|
1,102 | 246 | 590 | 16,405 | 763 | 4,029 |
Protein | Taxonomy | atazanavir sulfate (IC50) | chloroquine (IC50) |
---|---|---|---|
glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase | Plasmodium berghei | 43 | |
Spike glycoprotein | Betacoronavirus England 1 | 5.47 | |
Replicase polyprotein 1ab | Betacoronavirus England 1 | 5.47 | |
Transmembrane protease serine 2 | Homo sapiens (human) | 5.47 | |
Dihydrofolate reductase | Bos taurus (cattle) | 0.0301 | |
Amyloid-beta precursor protein | Homo sapiens (human) | 7 | |
Histidine-rich protein PFHRP-II | Plasmodium falciparum (malaria parasite P. falciparum) | 0.2383 | |
Procathepsin L | Homo sapiens (human) | 5.47 | |
Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
Replicase polyprotein 1ab | Human coronavirus 229E | 5.47 | |
Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
Spike glycoprotein | Severe acute respiratory syndrome coronavirus 2 | 3.58 | |
Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 6.375 | |
Ribosyldihydronicotinamide dehydrogenase [quinone] | Homo sapiens (human) | 1.5 | |
Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.27 | |
Beta-secretase 1 | Homo sapiens (human) | 7 | |
Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 2.503 | |
Angiotensin-converting enzyme 2 | Homo sapiens (human) | 6.235 | |
Cysteine proteinase falcipain 2a | Plasmodium falciparum (malaria parasite P. falciparum) | 0.02 | |
Cysteine proteinase falcipain 2a | Plasmodium falciparum (malaria parasite P. falciparum) | 0.2 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 2 (66.67) | 2.80 |
Authors | Studies |
---|---|
Chen, L; Chen, X; He, Z; Peng, N; Qin, L; You, J | 1 |
Ma, C; Wang, J | 1 |
Huang, YY; Li, Z; Lin, Y; Liu, R; Luo, HB; Wang, X; Zhan, CG | 1 |
3 other study(ies) available for atazanavir sulfate and chloroquine
Article | Year |
---|---|
Synergy of human immunodeficiency virus protease inhibitors with chloroquine against Plasmodium falciparum in vitro and Plasmodium chabaudi in vivo.
Topics: Animals; Antimalarials; Atazanavir Sulfate; Chloroquine; Drug Resistance; Drug Synergism; Female; HIV Protease Inhibitors; Humans; In Vitro Techniques; Lopinavir; Malaria; Mice; Nelfinavir; Oligopeptides; Plasmodium chabaudi; Plasmodium falciparum; Pyridines; Pyrimidinones; Ritonavir; Saquinavir | 2008 |
Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors.
Topics: Acetates; Atazanavir Sulfate; Benzimidazoles; Biphenyl Compounds; Chloroquine; COVID-19 Drug Treatment; Cyclopropanes; Dipyridamole; Humans; Oxytetracycline; Pharmaceutical Preparations; Protease Inhibitors; Quinolines; SARS-CoV-2; Sulfides; Tetrazoles | 2021 |
Reply to Ma and Wang: Reliability of various in vitro activity assays on SARS-CoV-2 main protease inhibitors.
Topics: Acetates; Atazanavir Sulfate; Benzimidazoles; Biphenyl Compounds; Chloroquine; COVID-19 Drug Treatment; Cyclopropanes; Dipyridamole; Humans; Oxytetracycline; Protease Inhibitors; Quinolines; Reproducibility of Results; SARS-CoV-2; Sulfides; Tetrazoles | 2021 |